Chen et al. (141) demonstrated that, in breast cancer cells, the isoflavone calycosin activates ERβ, and this is followed by a decreased activity of the PI3K/Akt pathway; on the other hand, calycosin did not affect the activity of the MAPK/ERK cascade. Here, ESR2 is linked to breast carcinoma.